Trials / Completed
CompletedNCT02796183
The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Neon Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the effects of subconjunctivally injected bevacizumab in patients with diffuse diabetic macular edema.
Detailed description
At baseline, the macular thicknesses of both eyes of the patients with persistant diabetic macular edema were measured by optical coherence tomography. After 3.75mg bevacizumab was injected into subconjunctival space of the eyes with diabetic macular edema. The measurements of the macular thicknesses were repeated by optical coherence tomography in 15th, 30th, 60th day after injections. The macular thickness measurements before and after injection were compared.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Subconjunctival bevacizumab (Altuzan) | Subconjunctival injections of Altuzan 3.75mg were applied in order to eliminate the macular edema. |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2016-04-01
- Completion
- 2016-05-01
- First posted
- 2016-06-10
- Last updated
- 2016-06-10
Source: ClinicalTrials.gov record NCT02796183. Inclusion in this directory is not an endorsement.